5-year real-world outcomes with first-line pembrolizumab plus chemotherapy in advanced/metastatic NSCLC.
Saved in:
| Title: | 5-year real-world outcomes with first-line pembrolizumab plus chemotherapy in advanced/metastatic NSCLC. |
|---|---|
| Authors: | Liu SV; Department of Medical Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA., Babel RA; Value & Implementation Outcomes Research, Oncology, Merck & Co., Inc., Rahway, NJ, USA., Kao YH; Biostatistics and Research Decision Sciences (BARDS), Merck & Co., Inc., Rahway, NJ, USA., Chirovsky D; Value & Implementation Outcomes Research, Oncology, Merck & Co., Inc., Rahway, NJ, USA., Namakydoust A; Oncology Clinical Development, Merck & Co., Inc., Rahway, NJ, USA., Velcheti V; Perlmutter Cancer Center, New York University Langone Health, New York, NY, USA. |
| Source: | Immunotherapy [Immunotherapy] 2025 Oct; Vol. 17 (14), pp. 1005-1013. Date of Electronic Publication: 2025 Oct 17. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101485158 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1750-7448 (Electronic) Linking ISSN: 1750743X NLM ISO Abbreviation: Immunotherapy Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1750-7448 |
|---|---|
| DOI: | 10.1080/1750743X.2025.2569856 |
